BioTuesdays

Tag - MATN

Mateon taking VDAs in new direction against cancer

Mateon Therapeutics (NASDAQ:MATN) is developing vascular disrupting agents (VDAs) that selectively disrupt abnormal tumor blood vessels, which supply nutrients to cancer cells, with an initial clinical focus on platinum...

Subscribe

Sign up to our weekly BioTuesdays newsletter.